Literature DB >> 20102310

Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology.

Annie Im1, Leonard J Appleman.   

Abstract

IMPORTANCE OF THE FIELD: Mifepristone is a synthetic selective progesterone-receptor modulator (SPRM) that is widely used around the globe in the field of reproductive medicine. At present mifepristone is approved in a number of countries for early termination of pregnancy (TOP), cervical dilatation before surgical TOP, and management of early embryonic loss or fetal death. A number of new clinical applications are being developed in gynecology, endocrinology and oncology. Mifepristone has also served as an invaluable tool in the study of steroid hormone biology. AREAS COVERED IN THIS REVIEW: Current indications for mifepristone are reviewed. New applications for mifepristone under clinical investigation are discussed. In addition, the unique molecular and cellular effects of mifepristone are described. WHAT THE READER WILL GAIN: The reader will understand the mechanisms of action of mifepristone and the underlying steroid hormone biology. The reader will know the approved clinical indications for mifepristone and appreciate the ongoing basic and clinical research into new applications. TAKE HOME MESSAGE: Mifepristone is the first-discovered and still most widely used antiprogestin. It has several indications in reproductive medicine and is under investigation for a variety of potential applications in other fields of medicine. The molecular and cellular effects of mifepristone illuminate important aspects of steroid hormone biology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102310     DOI: 10.1517/14656560903535880

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

1.  Towards a Treatment for Gulf War Illness: A Consensus Docking Approach.

Authors:  Rajeev Jaundoo; Jonathan Bohmann; Gloria E Gutierrez; Nancy Klimas; Gordon Broderick; Travis J A Craddock
Journal:  Mil Med       Date:  2020-01-07       Impact factor: 1.437

2.  Effect of Wujia Shenghua capsule on uterine bleeding following medically-induced incomplete abortion in rats during early pregnancy.

Authors:  Haiyang Liu; Wei Ma; Q I Liu; Fashan Wang; Ling Cao; Tienan Li; Ning Zhang; Fang Geng
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

3.  Progesterone analogs influence germination of Clostridium sordellii and Clostridium difficile spores in vitro.

Authors:  Marc Liggins; Norma Ramirez; Natiera Magnuson; Ernesto Abel-Santos
Journal:  J Bacteriol       Date:  2011-04-08       Impact factor: 3.490

4.  Medical termination of pregnancy in cynomolgus macaques.

Authors:  Elizabeth Micks; Taylor Shekell; Jessica Stanley; Mary Zelinski; Lauren Martin; Serena Riefenberg; Tiffany Adevai; Jeffrey Jensen
Journal:  J Med Primatol       Date:  2012-10-18       Impact factor: 0.667

5.  Progesterone receptor (PR) variants exist in breast cancer cells characterised as PR negative.

Authors:  David M W Cork; Thomas W J Lennard; Alison J Tyson-Capper
Journal:  Tumour Biol       Date:  2012-09-07

6.  Endometriosis: alternative methods of medical treatment.

Authors:  Leticia Muñoz-Hernando; Jose L Muñoz-Gonzalez; Laura Marqueta-Marques; Carmen Alvarez-Conejo; Álvaro Tejerizo-García; Gregorio Lopez-Gonzalez; Emilia Villegas-Muñoz; Angel Martin-Jimenez; Jesús S Jiménez-López
Journal:  Int J Womens Health       Date:  2015-06-11

7.  Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin.

Authors:  Heather E Kapperman; Alicia A Goyeneche; Carlos M Telleria
Journal:  Cancer Cell Int       Date:  2018-11-15       Impact factor: 5.722

8.  Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism.

Authors:  Soraya L Valles; María Benlloch; María L Rodriguez; Salvador Mena; José A Pellicer; Miguel Asensi; Elena Obrador; José M Estrela
Journal:  J Transl Med       Date:  2013-03-22       Impact factor: 5.531

9.  Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches.

Authors:  Piotr Jurka; Lidia Szulc-Dąbrowska; Joanna Borkowska; Anna Winnicka
Journal:  BMC Vet Res       Date:  2013-10-26       Impact factor: 2.741

Review 10.  Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies.

Authors:  Andrea Wagenfeld; Philippa T K Saunders; Lucy Whitaker; Hilary O D Critchley
Journal:  Expert Opin Ther Targets       Date:  2016-05-14       Impact factor: 6.902

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.